The active ingredient is the medicinal yeast Saccharomyces cerevisiae HANSEN CBS 5926, also known as Saccharomyces boulardii, which has been extensively studied in clinical trials for various causes of diarrhoea.2 This unique pro- and prebiotic helps combat common bacterial pathogens, supports the regeneration of the intestinal mucosa in cases of viral infections, and helps maintain normal bowel motility. At the same time, Saccharomyces boulardii promotes the growth of beneficial intestinal bacteria and supports the restoration of the individual gut microbiome.
New appearance, trusted quality
With the packaging relaunch, the key brand messages of Perenterol® will become even more visible in the future. The modernised design in subtle shades of green conveys quality, trustworthiness, and medical expertise at first glance. At the same time, the consistent visual identity makes it easier to recognise the products in pharmacies.
Most importantly for users, the formulations remain unchanged. The pharmaceutical identification numbers (PZN) will also remain the same.
Gradual transition in the market
The new packaging will be introduced to the market step by step. Products featuring the previous design will remain fully marketable and can continue to be used without any restrictions.
For more information about Perenterol®, please visit the website Perenterol. If you have any questions, your local sales representative and the MEDICE Customer Service Center will also be happy to assist you.
1Institute for Quality and Efficiency in Health Care (IQWiG). Diarrhoea. IQWiG Information on Diarrhoea (accessed 12 August 2026)
2McFarland L. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202-22.
Mandatory information:
Perenterol® forte 250 mg Capsules
Active ingredient: Dried yeast from Saccharomyces cerevisiae HANSEN CBS 5926 (synonym: Saccharomyces boulardii). Composition: Each hard capsule contains 250 mg dried yeast from Saccharomyces cerevisiae HANSEN CBS 5926, corresponding to at least 1.8 × 10¹⁰ viable cells/g lyophilisate. Other ingredients: Lactose monohydrate, magnesium stearate (Ph. Eur.), gelatin, sodium lauryl sulfate, colouring agent: titanium dioxide (E171). Indications: For the treatment of symptoms associated with acute diarrhoeal diseases, for the prevention and treatment of travellers’ diarrhoea, and diarrhoea associated with tube feeding. As an adjunctive treatment for persistent forms of acne. For adults and children aged 2 years and older. Contraindications: Known hypersensitivity to any of the ingredients, yeast allergy, particularly to Saccharomyces boulardii; patients with central venous catheters (CVCs); critically ill or immunosuppressed patients due to the risk of fungaemia. For adults and children aged 2 years and older. Infants and children under 2 years of age should not be self-medicated under any circumstances and should only be treated after consultation with a physician. Pregnancy and breastfeeding: Do not use during pregnancy or breastfeeding. Side effects: Very rare: fungaemia in patients with central venous catheters and in critically ill or immunosuppressed patients. Frequency not known: hypersensitivity reactions including itching, urticaria, localized or generalized rash, angioedema, shortness of breath and anaphylactic shock, sepsis, flatulence, and constipation. Warning: Contains lactose. Information status: August 2024. MEDICE Arzneimittel, 58638 Iserlohn, Germany.
Perenterol® Junior 250 mg Powder
Active ingredient: Dried yeast from Saccharomyces cerevisiae HANSEN CBS 5926 (synonym: Saccharomyces boulardii). Composition: Each sachet contains 250 mg dried yeast from Saccharomyces cerevisiae HANSEN CBS 5926, corresponding to at least 1.8 × 10¹⁰ viable cells/g lyophilisate. Other ingredients: Lactose monohydrate, fructose (Ph. Eur.), highly dispersed silicon dioxide, artificial tutti-frutti flavouring powder. Indications: For the treatment of symptoms associated with acute diarrhoeal diseases, including travellers’ diarrhoea and diarrhoea associated with tube feeding. For the prevention of travellers’ diarrhoea. For use in acute diarrhoea in children and adults aged 2 years and older, and in infants from 6 months of age following consultation with a physician. For the prevention of travellers’ diarrhoea from 12 years of age. Contraindications: Known hypersensitivity to any of the ingredients, yeast allergy, particularly to Saccharomyces boulardii; patients with central venous catheters (CVCs); critically ill or immunosuppressed patients due to the risk of fungaemia. Pregnancy and breastfeeding: Do not use during pregnancy or breastfeeding. Side effects: Very rare: fungaemia in patients with central venous catheters and in critically ill or immunosuppressed patients. Frequency not known: hypersensitivity reactions including itching, urticaria, localized or generalized rash, angioedema, shortness of breath and anaphylactic shock, sepsis, flatulence, and constipation. Warning: Contains lactose, fructose and sorbitol. Information status: August 2024. MEDICE Arzneimittel, 58638 Iserlohn, Germany.
:focal())